Drug Trial Radar · NCT05207670
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
320
Actual
Start
Feb 1, 2022
Primary completion
Oct 1, 2027
Study completion Oct 29, 2027
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jan 26, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy, safety, and pharmacokinetics of mosunetuzumab subcutaneous (SC) formulation in participants with selected B-cell malignancies (types of non-Hodgkin's lymphoma \[NHL\]).
Conditions
- Non-Hodgkin Lymphoma
Interventions
Mosunetuzumab (Cohorts A-C)Drug
Participants will receive SC mosunetuzumab for up to 17 cycles and for optional maintenance (Cohort A only)
Mosunetuzumab (Cohorts D-E)Drug
Participants will receive SC mosunetuzumab for up to 34 cycles
TocilizumabDrug
Participants can be treated with tocilizumab if they present with CRS after receiving mosunetuzumab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS) rate at 24 months after the first study treatment (Cohorts A1, A2, and B)Time frame: From the first study treatment to the first occurrence of disease progression, relapse, or death from any cause, whichever occurs first, as determined by the investigator according to Lugano Criteria 2014 (minimum 2 years)
- Objective response rate (ORR), defined as the proportion of participants with a complete metabolic response (CMR) or partial response (PR), as determined by the investigator according to the Lugano Criteria 2014 (Cohorts C, D, and E)Time frame: Cycles 4, 8, 12 and 17 (cycle length=21 days)
Locations
39 sites in 1 country. Site status is shown where the registry gives one.
Infirmary Cancer Care
Mobile, Alabama
Alaska Oncology & Hematology, LLC
Anchorage, Alaska
Mayo Clinic Arizona
Phoenix, Arizona
City of Hope
Duarte, California
Rocky Mountain Cancer Centers (Aurora) - USOR
Aurora, Colorado
Medical Oncology Hematology Consultants
Newark, Delaware
SCRI Florida Cancer Specialists South
Fort Myers, Florida
Mayo Clinic Jacksonville - PPDS
Jacksonville, Florida
Cancer Specialists of North Florida - Jacksonville
Jacksonville, Florida
Florida Cancer Specialists - NORTH - SCRI - PPDS
St. Petersburg, Florida
Florida Cancer Specialists - EAST - SCRI - PPDS
West Palm Beach, Florida
Mission Blood and Cancer - MercyOne Cancer Center
Des Moines, Iowa
University of Kansas Medical Center
Westwood, Kansas
Oncology Hematology Care - SCRI
Zachary, Louisiana
American Oncology Partners of Maryland, PA
Bethesda, Maryland
Mayo Clinic - PPDS
Rochester, Minnesota
St. Vincent Frontier Cancer Center
Billings, Montana
Astera Cancer Care East Brunswick
East Brunswick, New Jersey
San Juan Oncology Associates
Farmington, New Mexico
New York Oncology Hematology, P.C.
Albany, New York
New York Cancer & Blood Specialists - New Hyde Park
New Hyde Park, New York
NY Cancer & Blood Specialist
New York, New York
North Shore Hematology Oncology Association PC
Shirley, New York
New York Cancer & Blood Specialists - Bronx
The Bronx, New York
Oncology Hematology Care Inc - Cincinnati - USOR
Cincinnati, Ohio
Oncology Associates of Oregon, P.C.
Eugene, Oregon
Providence Cancer Institute
Portland, Oregon
Kaiser Foundation Hospitals
Portland, Oregon
McGlinn Cancer Institute at Reading Hospital
West Reading, Pennsylvania
Tennessee Oncology Chattanooga
Chattanooga, Tennessee
Tennessee Oncology - Nashville
Nashville, Tennessee
Texas Oncology (Amarillo) - USOR - 1826 Point West Pkwy
Amarillo, Texas
Texas Oncology-Austin Midtown
Austin, Texas
Texas Oncology (Worth) - USOR
Dallas, Texas
Texas Oncology (Tyler) - USOR
Tyler, Texas
Virginia Cancer Specialists - Gainsville
Gainesville, Virginia
Kadlec Clinic Hematology and Oncology
Kennewick, Washington
VA Puget Sound Health Care System - NAVREF - PPDS
Seattle, Washington
MultiCare Deaconess Cancer and Blood Specialty Center
Spokane, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.